Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Fortress biotech, inc. symbols : AZN save search
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
| Email alert
Add to watchlist
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
| Email alert
Add to watchlist
DERM | $3.54 -8.29% -9.04% 190K
|
| Email alert
Add to watchlist
MBIO | $0.3819 -0.55% -1.05% 200K
|
Health Technology
| Email alert
Add to watchlist
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
| Email alert
Add to watchlist
CKPT | $1.595 -4.49% -4.7% 470K
|
Health Technology
| Email alert
Add to watchlist
biotech financial results
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
Published: 2023-10-16 (Crawled : 13:00) - globenewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -4.43%
H: 3.6%
C: 3.6%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 0.34%
H: 4.12%
C: -4.81%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -1.07%
H: 2.0%
C: 1.82%
biotech worldwide hope cell treatment city agreement therapy living
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Published: 2023-08-14 (Crawled : 20:00) - globenewswire.com
DERM | $3.54 -8.29% -9.04% 190K
|
|
| O: -2.75%
H: 4.01%
C: -0.47%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -1.75%
H: 0.0%
C: -2.23%
MBIO | $0.3819 -0.55% -1.05% 200K
|
Health Technology
|
| O: 0.0%
H: 0.07%
C: -5.71%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: -8.92%
H: 0.0%
C: 0.0%
CKPT | $1.595 -4.49% -4.7% 470K
|
Health Technology
|
| O: -0.96%
H: 2.42%
C: -2.42%
ATXI | $0.1311 -2.96% -3.05% 290K
|
Health Technology
|
| O: -2.37%
H: 4.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -1.27%
H: 0.26%
C: -0.61%
biotech financial results
Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023
Published: 2023-08-03 (Crawled : 12:20) - globenewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 1.2%
H: 1.52%
C: -4.99%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -2.88%
H: 1.68%
C: 1.53%
conference biotech
Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
Published: 2023-06-29 (Crawled : 12:20) - globenewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 1.06%
H: 0.72%
C: 0.72%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 0.0%
H: 7.55%
C: 7.55%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.83%
H: 0.89%
C: 0.68%
topline trial therapeutics
Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
Published: 2023-06-15 (Crawled : 12:20) - globenewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 0.97%
H: 0.64%
C: 0.64%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 2.42%
H: 10.78%
C: 7.94%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 1.68%
H: 1.0%
C: 0.84%
cancer grant program trial phase 2
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Published: 2023-05-15 (Crawled : 20:00) - globenewswire.com
DERM | $3.54 -8.29% -9.04% 190K
|
|
| O: 2.41%
H: 8.42%
C: 1.01%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
MBIO | $0.3819 -0.55% -1.05% 200K
|
Health Technology
|
| O: 0.0%
H: 1.24%
C: -0.23%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 4.67%
H: 1.34%
C: -10.55%
CKPT | $1.595 -4.49% -4.7% 470K
|
Health Technology
|
| O: 1.41%
H: 2.79%
C: -2.79%
ATXI | $0.1311 -2.96% -3.05% 290K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.44%
H: 0.44%
C: -0.05%
biotech financial results
Fortress Biotech to Participate in Two March 2023 Investor Conferences
Published: 2023-03-07 (Crawled : 14:00) - globenewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -2.57%
H: 1.62%
C: 1.62%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 0.0%
H: 3.69%
C: 2.72%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.9%
H: 0.28%
C: -1.3%
biotech
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Published: 2023-02-16 (Crawled : 14:00) - globenewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -2.87%
H: 0.88%
C: 0.88%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 0.81%
H: 5.54%
C: 3.66%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -2.65%
H: 1.22%
C: 0.16%
cibmtr trial positive therapy
Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Published: 2023-02-10 (Crawled : 18:00) - globenewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 1.67%
H: 0.55%
C: 0.55%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: -2.71%
H: 6.03%
C: 2.7%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 1.77%
H: 0.56%
C: 0.39%
offering nasdaq biotech direct
Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Published: 2023-02-08 (Crawled : 15:20) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: -0.49%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: -14.99%
H: 12.71%
C: 6.31%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 1.52%
H: 0.02%
C: -1.39%
offering nasdaq biotech direct
Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors
Published: 2022-12-19 (Crawled : 13:20) - globenewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 0.99%
H: 0.06%
C: 0.06%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 0.4%
H: 0.4%
C: -3.99%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 3.79%
H: 3.82%
C: -8.21%
ATXI | $0.1311 -2.96% -3.05% 290K
|
Health Technology
|
| O: -0.81%
H: 1.63%
C: -6.5%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.07%
H: 0.01%
C: -0.62%
biotech
Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
Published: 2022-12-06 (Crawled : 15:00) - biospace.com/
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: -2.03%
H: 2.9%
C: -3.67%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.48%
H: 1.59%
C: 0.69%
conference biotech medical aesthetic
Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Published: 2022-11-14 (Crawled : 22:00) - globenewswire.com
DERM | $3.54 -8.29% -9.04% 190K
|
|
| O: 3.37%
H: 0.0%
C: -2.83%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: -1.79%
MBIO | $0.3819 -0.55% -1.05% 200K
|
Health Technology
|
| O: -4.08%
H: 8.87%
C: 1.83%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 2.68%
H: 0.0%
C: 0.0%
ATXI | $0.1311 -2.96% -3.05% 290K
|
Health Technology
|
| O: -3.85%
H: 2.86%
C: -5.14%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 1.05%
H: 0.36%
C: -0.98%
biotech financial results
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Published: 2022-11-10 (Crawled : 00:00) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 6.22%
H: 3.13%
C: -0.56%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 0.17%
H: 6.48%
C: -1.81%
ATXI | $0.1311 -2.96% -3.05% 290K
|
Health Technology
|
| O: -10.64%
H: 30.29%
C: 25.6%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 7.08%
H: 0.84%
C: -0.43%
therapeutics financial results
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
Published: 2022-11-08 (Crawled : 14:20) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 2.49%
H: 0.0%
C: -1.6%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 0.0%
H: 4.76%
C: -4.6%
ATXI | $0.1311 -2.96% -3.05% 290K
|
Health Technology
|
| O: 7.78%
H: 6.67%
C: -7.78%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.2%
H: 0.96%
C: 0.18%
treatment acquisition system therapeutics positive
Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
Published: 2022-10-05 (Crawled : 17:00) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -1.24%
H: 1.81%
C: 0.48%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: -0.01%
H: 4.52%
C: 2.06%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -1.74%
H: 1.53%
C: 1.21%
biotech
Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
Published: 2022-10-03 (Crawled : 13:00) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 2.29%
H: 1.55%
C: 1.55%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 1.16%
H: 1.13%
C: -1.89%
ATXI | $0.1311 -2.96% -3.05% 290K
|
Health Technology
|
| O: 38.59%
H: 11.02%
C: -17.61%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.42%
H: 1.08%
C: 0.87%
biotech therapeutics
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex
Published: 2022-08-11 (Crawled : 14:00) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -0.07%
H: 0.12%
C: -2.89%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 0.83%
H: 7.38%
C: 5.74%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -1.89%
H: 0.0%
C: -0.61%
biotech grant study phase 2
Fortress Biotech Appoints David Jin as Chief Financial Officer
Published: 2022-07-22 (Crawled : 13:20) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 2.95%
H: 0.28%
C: -0.48%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 0.98%
H: 0.0%
C: -7.76%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.29%
H: 0.87%
C: 0.12%
biotech
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.